Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions.

Abstract

A 52-year-old woman with ulcerative colitis was admitted to our hospital for an ulcerative colitis flare-up under salazosulfapyridine therapy. The symptoms improved with high-dose corticosteroids. After prednisolone was tapered to 10 mg, the frequency of diarrhea increased. The diarrhea was accompanied by joint pain and a skin ulcer with abscess formation, which was diagnosed to be pyoderma gangrenosum. The patient was started on adalimumab. A positive response to the adalimumab therapy was observed after 2 weeks, during which time the ulcerative skin lesion healed completely, however, colonic mucosal healing was achieved at 2 months. Therefore, adalimumab appears to be an effective therapeutic option for patients with ulcerative colitis-associated pyoderma gangrenosum.

• Authors: Shintaro Sagami, Yoshitaka Ueno, Shinji Tanaka, Kenta Nagai, Ryohei Hayashi, Kazuaki Chayama
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 54 Issue 17 Pg. 2167-72 ( 2015) ISSN: 1349-7235 [Electronic] Japan
• PMID: 26328641 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adrenal Cortex Hormones
• Anti-Inflammatory Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Sulfasalazine
• Prednisolone
• Adalimumab

Topics

• Adalimumab (administration & dosage, therapeutic use)
• Adrenal Cortex Hormones (administration & dosage)
• Anti-Inflammatory Agents (administration & dosage, therapeutic use)
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)
• Colitis, Ulcerative (complications, drug therapy)
• Female
• Humans
• Middle Aged
• Prednisolone (administration & dosage)
• Pyoderma Gangrenosum (drug therapy, etiology)
• Skin Ulcer (complications, drug therapy, pathology)
• Sulfasalazine (administration & dosage)
• Treatment Failure
• Treatment Outcome